Identification of Drug-related and Formulation-Related Factors that Result in Alcohol Dose Dumping of Modified Release Oral Drug Products (U01) Clinical Trial Not Allowed
Forecast: not open for applications yet. Dates are the funder's estimate. Save a search and Brieflist marks it when it opens (Grants Pro e-mails you), or get the free weekly digest:
This is a forecast: the funder has announced the grant but applications are not open yet. Dates may change.
Modified release (MR) oral drug products are considered to have a high risk for alcohol dose dumping (ADD) because they contain large quantities of drug(s), designed to release over a prolonged period of time.
Read the official page on Grants.gov ↗ Get new grants like this
- Funder
- Food and Drug Administration (Department of Health and Human Services)
- Where
- 🇺🇸 United States
- Status
- Forecast
- Funding
- Up to $250k per award
- Expected awards
- 1
- Who can apply
- Most organisations
- Topics
- Agriculture & food Justice & security
- Opportunity number
- FOR-FD-24-006
- Instrument
- Cooperative agreement
About this grant
Modified release (MR) oral drug products are considered to have a high risk for alcohol dose dumping (ADD) because they contain large quantities of drug(s), designed to release over a prolonged period of time. Accidental exposure of these products to alcohol can result in the relatively rapid release of large quantities of drug with severe side effects, including death. To mitigate this risk, the FDA recommends conducting an in vitro alcohol dose dumping assessment in 0%, 5%, 20%, and 40% alcoholic dissolution media for all prospective generic versions of MR oral drug products.
To date, ADD assessments have not been harmonized globally. For instance, the U.S. FDA recommends testing up to 40% alcoholic media while the European Medicines Agency recommends testing up to 20% alcoholic media. This type of difference can present a challenge for formulators designing products for multiple markets, as historical data has shown release from MR oral products do not always follow a linear response (either increasing or decreasing) to increasing alcohol concentrations. In addition, interpretation of an ADD assessment may be limited by the inability of the test to predict in vivo behavior.
The purpose of this research is to develop tools that 1) facilitate the development of MR generic drug products that have a low potential for ADD, 2) support regulatory decision making during the assessment of such products, and 3) provide evidence that enables FDA to develop more specific recommendations for efficiently demonstrating a low or comparative potential of alcohol dose dumping for MR oral drug products containing high risk drugs.
Eligibility
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"; Public and State controlled institutions of higher education; Native American tribal governments (Federally recognized); Native American tribal organizations (other than Federally recognized tribal governments); Special district governments; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Independent school districts; Small businesses; State governments; City or township governments; Public housing authorities/Indian housing authorities; County governments; For profit organizations other than small businesses. Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The FDA will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submission of Resubmission Application. This means that the NIH or FDA will not accept:•A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.•A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.•An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).
Applying for grants? Grants Pro e-mails you every morning with the new grants and opened forecasts that match your saved searches, and adds deadline reminders in your calendar, a private RSS feed and CSV export. Try it free for 7 days, then $9/month, cancel any time. See what Pro does →
More from this funder: 12 open opportunities from Food and Drug Administration (FDA).
Applying? Read how to write a winning grant proposal.
Data from Grants.gov, US federal government (public domain). Last checked 19 Nov 2026. Always read the official page before applying: it has the full conditions, documents and how to apply.